August 28, 2024

The RMPDS Annual Scientific Meeting strives to connect industry, academia, and regulatory experts to discuss the latest trends in prescription drug misuse and diversion.

This year we focus on: Emerging Surveillance Needs for Psychoactive Drugs.

The event will include lively discussions and presentations from an esteemed list of guest speakers, including internal personnel and industry peers.

Agenda items will include:

• The ever-changing landscape of the prescription drug crisis
• Emerging surveillance data opportunities
• Mortality within the landscape
• New model of surveillance to assess benefits & risks of psychedelics
• Data and trends around psychedelics

Meeting Agenda

Nabarun Dasgupta, PhD, MPH

Fellow at University of North Carolina Gillings School of Public Health, Senior Scientist at UNC Chapel Hill, and Co-Founder of Remedy Alliance for the People

Neeraj Gandotra, MD

Chief Medical Officer, Substance Abuse and Mental Health Services Administration (SAMHSA) 

Erica Siegal, LCSW

Harm Reduction Advocate and Psychedelic Psychotherapist, CEO - NEST Harm Reduction & Consulting

Marta Sokolowska, PhD

Deputy Center Director for Substance Use and Behavioral Health (Center for Drug Evaluation and Research (CDER), Food and Drug Administration)

Joshua Black, PhD

Senior Research Scientist, Rocky Mountain Poison & Drug Safety

Richard C. Dart, MD, PhD

Director, Rocky Mountain Poison & Drug Safety. President, Canadian Consumer Product and Pharmaceutical Safety Inc. Professor of Emergency Medicine & Medical Toxicology and Pharmacology, University of Colorado

Andrew A. Monte, MD, PhD

Scientific Director of Research, Rocky Mountain Poison & Drug Safety. Medical Director of Rocky Mountain Drug Center & Denver Health Nurseline. Professor of Emergency Medicine & Medical Toxicology and Pharmacology, University of Colorado Health Sciences Center